Efficacy of LL-37 and granulocyte colony-stimulating factor in a neutropenic murine sepsis due to Pseudomonas aeruginosa

Shock

Volumn 30, Issue 4, 2008, Pages 443-448

  Cirioni, Oscar ^a,f   Ghiselli, Roberto ^a   Tomasinsig, Linda ^b   Orlando, Fiorenza ^c   Silvestri, Carmela ^a   Skerlavaj, Barbara ^b   Riva, Alessandra ^a   Rocchi, Marco ^d   Saba, Vittorio ^a   Zanetti, Margherita ^b,e   Scalise, Giorgio ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c INRCA   (Italy)

^d UNIVERSITY OF URBINO   (Italy)

^e National Laboratory CIB   (Italy)

^f C/o Ospedale Regionale ^*  (Italy)

Author keywords

Cathelicidin; G CSF; Gram negative sepsis; LL 37; Neutropenia

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; LETHALITY; MALE; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PSEUDOMONAS AERUGINOSA; SEPSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEUTROPENIA; NEUTROPHILS; PEPTIDES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEPSIS;

EID: 54049126498     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31816d2269     Document Type: Article

References (34)

1. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, Beach M: Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 29:595-607, 1999.
2. Klastersky J: Management of fever in neutropenic patients with different risk of complications. Clin Infect Dis 39:S32-S37, 2004.
3. Cordonnier C, Herbrecht R, Buzin A, Leverger G, Leclercq R, Nitenberg G, Bastuji-Garin S: Club de Reflexion sur les Infections en Onco-Hématologie group: risk factors for gram-negative bacterial infections febrile neutropenia. Haematologica 90:1102-1109, 2005.
4. Bisbe J, Gatell JM, Puig J, Mallolas J, Martinez JA, Jimenez de Anta MT, Soriano E: Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factor influencing the prognosis in 133 episodes. Rev Infect Dis 10:629-635, 1988.
5. Chamot E, Boffi El Amari E, Rohner P, Van Delden C: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 47:2756-2764, 2003.
6. Forkne CE, Frei E, Edgcomb JH, Utz JP: Pseudomonas septicemia. Am J Med 25:877-888, 1957.
7. Hughes WT, Armstrong D, Bodey GP, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS: Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730-751, 2002.
8. Livermore DM: Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis Suppl 1:S11-S23, 2003.
9. Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: pathogenesis. Lancet 338:732-736, 1991.
10. Bochud PY, Calandra T: Pathogenesis of sepsis: new concepts and implications for future treatment. Br Med J 326:262-266, 2003.
11. Grigull L, Pulver N, Goudeva L, Sykora KW, Linderkamp C, Beilken A, Seidemann K, Schmid H, Welte K, Heuft HG: G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis. Support Care Cancer 14:910-916, 2006.
12. Marshall JC: The effects of granulocyte colony-stimulating factor in preclinical models of infection and acute inflammation. Shock 24:S120-S129, 2005.
13. McLemore ML, Poursine-Laurent J, Link DC: Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest 102:483-492, 1998.
14. Barreda DR, Hanington PC, Belosevic M: regulation of myeloid development and function by colony-stimulating factors. Dev Comp Immunol 28:509-554, 2004.
15. Deleted in proof.
16. Bernstein HM, Calhoun DA, Christensen RD: Use of myeloid colony-stimulating factors in neonates with septicemia. Curr Opin Pediatr 14:91-94, 2002.
17. Boman HG: Antibacterial peptides: basic facts and emerging concepts. J Int Med 254:197-215, 2003.
18. Hancock REW: Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1:156-164, 2001.
19. Hancock REW, Scott MG: The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 97:856-861, 2000.
20. Zanetti M: Cathelicidins, multifunctional peptides of the innate immunity. J Leuk Biol 75:39-48, 2004.
21. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R: The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 238:325-332, 1996.
22. Zanetti M: The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol 7:179-196, 2005.
23. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Silvestri C, Mocchegiani F, Licci A, Skerlavaj B, Saba V, et al.: LL-37 protects rats against lethal gram-negative sepsis. Antimicrob Agents Chemother 50:1672-1679, 2006.
24. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC: Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 63:1291-1297, 1995.
25. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, et al.: Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176:2455-2464, 2006.
26. Clinical and Laboratory Standards Institute: Methods for dilution anti-microbial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. Villanova. PA: Clinical and Laboratory Standards Institute, 2003.
27. Maianski NA, Roos D, Kuijpers TW: Bid truncation, bid/bax targeting to the mitochondria, and caspase activation associated with neutrophil apoptosis are inhibited by granulocyte colony-stimulating factor. J Immunol 172:7024-7030, 2004.
28. Nagaoka I, Tamura H, Hirata M: An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor- like 1 and P2X7. J Immunol 176:3044-3052, 2006.
29. Opal SM, Cross AS: The use of immunocompromised animals as models for human septic shock. Shock 24:S64-S70, 2005.
30. Opal SM, Cross AS: The use of immunocompromised animals in sepsis research. Sepsis 2:235-242, 1999.
31. Bowdish DME, Davidson DJ, Speert DP, Hancock RE: The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J Immunol 172:3758-3767, 2004.
32. Bowdish DME, Davidson DJ, Scott MG, Hancock RE: Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49:1727-1732, 2005.
33. De Yang L, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemo attract human peripheral blood neutrophils, monocytes, and cells. J Exp Med 192:1069-1074, 2000.
34. Oren Z, Shai Y: Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47:451-463, 1998.